“anti-TNF drugs”的搜索结果，显示 91-100 项，共有 969 项

1. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

2. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

3. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

4. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

5. 肺科- 临床试验- 妙佑医疗国际

   Rochester, Minn. The purpose of this study is to determine whether 2-drug therapy is non-inferior to 3-drug therapy against pulmonary mycobacterium avium ...

6. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

7. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

8. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

9. 神经科- 临床试验- 妙佑医疗国际

   ... Therapy. Rochester, Minn. The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as ...

10. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...